Diagnostics
Researchers from Amen Clinics in Costa Mesa, California, Google, John’s Hopkins University, University of California, Los Angeles and the University of California, San Francisco studied 62,454 brain scans of more than 30,000 people to study brain aging.
Massachusetts in general and Boston, specifically Cambridge, is one of the two largest centers in the U.S. for biotech startups and life science companies (the other being the San Francisco Bay Area). Here’s a look at 13 Massachusetts life science companies that are showing both gains and losses—mostly gains—at the six-month mark.
San Francisco-based Mammoth Biosciences, co-founded by one of the originators of CRISPR gene editing, Jennifer Doudna, closed on a $23 million Series A financing round.
Arc Bio launched its proprietary antimicrobial resistance (AMR) software. It is the first in what it expects to be a series of next-generation sequencing (NGS)-based products for pathogen detection.
Some diagnostics testing for infectious diseases can be quite invasive and uncomfortable for a patient. Now though, a new form of test is available that can mitigate the need for those invasive tests.
Recent studies in early diagnostics underline just how much focus medical technology companies are making on developing different modalities for very early cancer diagnosis. Here are just some recent examples.
There are plenty of great scientific research stories out this week including a possible cure for diabetes, healing spinal injury and more.
Swiss-based Ava markets the Ava bracelet, what it calls a cycle-tracking sensor bracelet. It is being sold as a way to track a woman’s fertile period, although the company suggests it plans to see if it can be used as a type of birth control.
Advances in data storage and processing, as well as biomarker identification, has led to cutting-edge breakthroughs in clinical and research imaging technology. Here’s a look at just a few of these stories.
With a new chief executive officer on board, GRAIL, Inc. has secured a whopping $300 million in an oversubscribed Series C financing round led by multiple Chinese investment groups.
PRESS RELEASES